ELOXX PHARMACEUTICALS, INC. Research and Development Expense
ELOXX PHARMACEUTICALS, INC. (ELOX) reported Research and Development Expense of $2.84 million for the 3-month period ending 2026-06-30, per its S-1 filed 2026-09-11.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-09-11
- ELOXX PHARMACEUTICALS, INC. research and development expense for the quarter ending 2026-06-30 was $2.84M, a 216.26% increase year-over-year.
- ELOXX PHARMACEUTICALS, INC. research and development expense for the quarter ending 2025-06-30 was $898.00K.
- ELOXX PHARMACEUTICALS, INC. research and development expense for the quarter ending 2021-03-31 was $4.07M, a 14.56% decline year-over-year.
- ELOXX PHARMACEUTICALS, INC. research and development expense for the quarter ending 2020-12-31 was $2.69M, a 56.54% decline year-over-year.
- ELOXX PHARMACEUTICALS, INC. research and development expense for fiscal 2020 was $14.59M, a 44.63% decline from fiscal 2019.
- ELOXX PHARMACEUTICALS, INC. research and development expense for fiscal 2019 was $26.35M, a 28.60% increase from fiscal 2018.
- ELOXX PHARMACEUTICALS, INC. research and development expense for fiscal 2018 was $20.49M, a 24.95% increase from fiscal 2017.
- ELOXX PHARMACEUTICALS, INC. research and development expense for fiscal 2017 was $16.40M, a 82.48% increase from fiscal 2016.
| Period end | Research and Development Expense 3 month | Research and Development Expense 3 month as first filed | Research and Development Expense 6 month | Research and Development Expense 6 month as first filed | Research and Development Expense 9 month | Research and Development Expense 9 month as first filed | Research and Development Expense 12 month | Research and Development Expense 12 month as first filed | Research and Development Expense 159 month | Research and Development Expense 162 month | Research and Development Expense 165 month | Research and Development Expense 168 month | Research and Development Expense 171 month | Research and Development Expense 174 month | Research and Development Expense 177 month | Research and Development Expense 180 month | Research and Development Expense 183 month | Research and Development Expense 186 month | Research and Development Expense 189 month |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $2.84M S-1 · filed 2026-09-11 | $4.50M S-1 · filed 2026-09-11 | |||||||||||||||||
| 2025-12-31 | $3.06M S-1 · filed 2026-09-11 | ||||||||||||||||||
| 2025-06-30 | $898.00K S-1 · filed 2026-09-11 | $1.41M S-1 · filed 2026-09-11 | |||||||||||||||||
| 2024-12-31 | $3.58M S-1 · filed 2026-09-11 | ||||||||||||||||||
| 2023-12-31 | $8.60M S-1 · filed 2026-09-11 | ||||||||||||||||||
| 2021-03-31 | $4.07M 10-Q · filed 2021-05-07 | $6.76M derived: sum of 2 quarters · filed 2021-05-07 | $10.16M derived: sum of 3 quarters · filed 2021-11-08 | $13.86M derived: sum of 4 quarters · filed 2021-11-08 | |||||||||||||||
| 2020-12-31 | $2.69M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-12 | $6.09M derived: sum of 2 quarters · filed 2021-11-08 | $9.79M derived: sum of 3 quarters · filed 2021-11-08 | $14.59M 10-K · filed 2021-03-12 | |||||||||||||||
| 2020-09-30 | $3.40M 10-Q · filed 2021-11-08 | $3.23M 10-Q · filed 2020-11-06 | $7.10M derived: sum of 2 quarters · filed 2021-11-08 | $11.90M 10-Q · filed 2021-11-08 | $11.31M 10-Q · filed 2020-11-06 | $18.06M derived: sum of 4 quarters · filed 2021-11-08 | |||||||||||||
| 2020-06-30 | $3.70M 10-Q · filed 2021-08-16 | $3.53M 10-Q · filed 2020-08-07 | $8.50M 10-Q · filed 2021-08-16 | $8.08M 10-Q · filed 2020-08-07 | $14.66M derived: sum of 3 quarters · filed 2021-08-16 | $21.46M derived: sum of 4 quarters · filed 2021-08-16 | |||||||||||||
| 2020-03-31 | $4.77M 10-Q · filed 2021-05-07 | $4.55M 10-Q · filed 2020-05-08 | $10.96M derived: sum of 2 quarters · filed 2021-05-07 | $17.76M derived: sum of 3 quarters · filed 2021-05-07 | $25.10M derived: sum of 4 quarters · filed 2021-05-07 | ||||||||||||||
| 2019-12-31 | $6.19M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-12 | $12.99M derived: sum of 2 quarters · filed 2021-03-12 | $20.33M derived: sum of 3 quarters · filed 2021-03-12 | $26.35M 10-K · filed 2021-03-12 | $25.84M 10-K · filed 2020-03-06 | ||||||||||||||
| 2019-09-30 | $6.80M 10-Q · filed 2020-11-06 | $14.14M derived: sum of 2 quarters · filed 2020-11-06 | $20.16M 10-Q · filed 2020-11-06 | $26.69M derived: sum of 4 quarters · filed 2021-03-12 | |||||||||||||||
| 2019-06-30 | $7.34M 10-Q · filed 2020-08-07 | $13.36M 10-Q · filed 2020-08-07 | $19.89M derived: sum of 3 quarters · filed 2021-03-12 | $25.30M derived: sum of 4 quarters · filed 2021-03-12 | |||||||||||||||
| 2019-03-31 | $6.02M 10-Q · filed 2020-05-08 | $12.55M derived: sum of 2 quarters · filed 2021-03-12 | $17.96M derived: sum of 3 quarters · filed 2021-03-12 | $22.11M derived: sum of 4 quarters · filed 2021-03-12 | |||||||||||||||
| 2018-12-31 | $6.53M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-12 | $11.95M derived: sum of 2 quarters · filed 2021-03-12 | $16.09M derived: sum of 3 quarters · filed 2021-03-12 | $20.49M 10-K · filed 2021-03-12 | |||||||||||||||
| 2018-09-30 | $5.42M 10-Q · filed 2019-11-06 | $9.56M derived: sum of 2 quarters · filed 2019-11-06 | $13.96M 10-Q · filed 2019-11-06 | $22.36M derived: sum of 4 quarters · filed 2019-11-06 | |||||||||||||||
| 2018-06-30 | $4.15M 10-Q · filed 2019-08-07 | $8.54M 10-Q · filed 2019-08-07 | $16.94M derived: sum of 3 quarters · filed 2019-08-07 | $20.22M derived: sum of 4 quarters · filed 2019-08-07 | |||||||||||||||
| 2018-03-31 | $4.39M 10-Q · filed 2019-05-09 | $4.01M 10-Q · filed 2018-05-10 | $12.79M derived: sum of 2 quarters · filed 2019-05-09 | $16.07M derived: sum of 3 quarters · filed 2019-05-09 | $18.67M derived: sum of 4 quarters · filed 2019-05-09 | ||||||||||||||
| 2017-12-31 | $8.40M 10-K · filed 2018-03-16 | $11.68M derived: sum of 2 quarters · filed 2018-11-08 | $14.28M derived: sum of 3 quarters · filed 2018-11-08 | $16.40M 10-K · filed 2020-03-06 | |||||||||||||||
| 2017-09-30 | $3.28M 10-Q · filed 2018-11-08 | $135.64K 10-Q · filed 2017-11-14 | $5.88M derived: sum of 2 quarters · filed 2018-11-08 | $8.23M 10-Q · filed 2018-11-08 | $8.44M derived: sum of 4 quarters · filed 2018-11-08 | ||||||||||||||
| 2017-06-30 | $2.60M 10-Q · filed 2018-08-10 | $4.95M 10-Q · filed 2018-08-10 | $5.16M derived: sum of 3 quarters · filed 2018-08-10 | $280.24K 10-Q · filed 2017-11-14 | $733.66K 10-K · filed 2017-10-13 | ||||||||||||||
| 2017-03-31 | $2.35M 10-Q · filed 2018-05-10 | $126.74K 10-Q · filed 2017-05-22 | $2.56M derived: sum of 2 quarters · filed 2018-05-10 | $614.36K 10-Q · filed 2017-05-22 | $3.25M derived: sum of 4 quarters · filed 2018-05-10 | ||||||||||||||
| 2016-12-31 | $207.38K 10-Q · filed 2017-02-10 | $487.62K 10-Q · filed 2017-02-10 | $898.08K derived: sum of 3 quarters · filed 2017-10-13 | $8.99M 10-K · filed 2019-03-14 | |||||||||||||||
| 2016-09-30 | $280.24K 10-Q · filed 2016-11-14 | $690.70K derived: sum of 2 quarters · filed 2017-10-13 | $1.27M derived: sum of 3 quarters · filed 2017-10-13 | $1.86M derived: sum of 4 quarters · filed 2017-10-13 | |||||||||||||||
| 2016-06-30 | $410.46K derived: 10-K 12 month − 10-Q 9 month · filed 2017-10-13 | $986.90K derived: sum of 2 quarters · filed 2017-10-13 | $1.58M derived: sum of 3 quarters · filed 2017-10-13 | $2.18M 10-K · filed 2017-10-13 | |||||||||||||||
| 2016-03-31 | $576.44K 10-Q · filed 2017-05-22 | $1.17M derived: sum of 2 quarters · filed 2017-05-22 | $1.77M 10-Q · filed 2017-05-22 | $2.61M derived: sum of 4 quarters · filed 2017-10-13 | |||||||||||||||
| 2015-12-31 | $594.50K 10-Q · filed 2017-02-10 | $1.20M 10-Q · filed 2017-02-10 | $2.04M derived: sum of 3 quarters · filed 2017-10-13 | $5.84M 10-K · filed 2018-03-16 | |||||||||||||||
| 2015-09-30 | $601.58K 10-Q · filed 2016-11-14 | $1.44M derived: sum of 2 quarters · filed 2017-10-13 | $1.68M derived: sum of 3 quarters · filed 2017-10-13 | $3.05M derived: sum of 4 quarters · filed 2017-10-13 | |||||||||||||||
| 2015-06-30 | $841.09K derived: 10-K 12 month − 10-Q 9 month · filed 2017-10-13 | $1.08M derived: sum of 2 quarters · filed 2017-10-13 | $2.45M derived: sum of 3 quarters · filed 2017-10-13 | $4.57M 10-K · filed 2017-10-13 | |||||||||||||||
| 2015-03-31 | $235.25K 10-Q · filed 2016-05-12 | $1.61M derived: sum of 2 quarters · filed 2016-05-12 | $3.73M 10-Q · filed 2016-05-12 | $4.56M derived: sum of 4 quarters · filed 2016-10-13 | |||||||||||||||
| 2014-12-31 | $1.37M 10-Q · filed 2016-02-16 | $3.49M 10-Q · filed 2016-02-16 | $4.32M derived: sum of 3 quarters · filed 2016-10-13 | $5.29M derived: sum of 4 quarters · filed 2016-10-13 | |||||||||||||||
| 2014-09-30 | $2.12M 10-Q · filed 2015-11-16 | $2.95M derived: sum of 2 quarters · filed 2016-10-13 | $3.92M derived: sum of 3 quarters · filed 2016-10-13 | $4.65M derived: sum of 4 quarters · filed 2016-10-13 | |||||||||||||||
| 2014-06-30 | $830.59K derived: 10-K 12 month − 10-Q 9 month · filed 2016-10-13 | $1.80M derived: sum of 2 quarters · filed 2016-10-13 | $2.53M derived: sum of 3 quarters · filed 2016-10-13 | $3.34M 10-K · filed 2016-10-13 | |||||||||||||||
| 2014-03-31 | $966.34K 10-Q · filed 2015-05-14 | $875.21K 10-Q · filed 2014-05-09 | $1.70M derived: sum of 2 quarters · filed 2015-05-14 | $2.51M 10-Q · filed 2015-05-14 | $2.25M 10-Q · filed 2014-05-09 | $3.00M derived: sum of 4 quarters · filed 2015-10-09 | $25.57M 10-Q · filed 2014-05-09 | ||||||||||||
| 2013-12-31 | $730.82K 10-Q · filed 2015-02-17 | $647.12K 10-Q · filed 2014-02-14 | $1.54M 10-Q · filed 2015-02-17 | $1.37M 10-Q · filed 2014-02-14 | $2.03M derived: sum of 3 quarters · filed 2015-10-09 | $2.52M derived: sum of 4 quarters · filed 2015-10-09 | $24.70M 10-Q · filed 2014-02-14 | ||||||||||||
| 2013-09-30 | $810.94K 10-Q · filed 2014-11-14 | $727.12K 10-Q · filed 2013-11-14 | $1.30M derived: sum of 2 quarters · filed 2015-10-09 | $1.79M derived: sum of 3 quarters · filed 2015-10-09 | $2.38M derived: sum of 4 quarters · filed 2015-10-09 | $24.05M 10-Q · filed 2013-11-14 | |||||||||||||
| 2013-06-30 | $489.30K derived: 10-K 12 month − 10-Q 9 month · filed 2015-10-09 | $982.15K derived: sum of 2 quarters · filed 2015-10-09 | $1.57M derived: sum of 3 quarters · filed 2015-10-09 | $2.09M 10-K · filed 2015-10-09 | $23.32M 10-K · filed 2013-09-11 | ||||||||||||||
| 2013-03-31 | $492.85K 10-Q · filed 2014-05-09 | $1.08M derived: sum of 2 quarters · filed 2014-05-09 | $1.60M 10-Q · filed 2014-05-09 | $2.24M derived: sum of 4 quarters · filed 2014-09-29 | $22.83M 10-Q · filed 2013-05-15 | ||||||||||||||
| 2012-12-31 | $591.08K 10-Q · filed 2014-02-14 | $1.10M 10-Q · filed 2014-02-14 | $1.74M derived: sum of 3 quarters · filed 2014-09-29 | $2.29M derived: sum of 4 quarters · filed 2014-09-29 | $22.34M 10-Q · filed 2013-02-14 | ||||||||||||||
| 2012-09-30 | $513.43K 10-Q · filed 2013-11-14 | $1.15M derived: sum of 2 quarters · filed 2014-09-29 | $1.69M derived: sum of 3 quarters · filed 2014-09-29 | $2.45M derived: sum of 4 quarters · filed 2014-09-29 | $21.75M 10-Q · filed 2012-11-14 | ||||||||||||||
| 2012-06-30 | $639.75K derived: 10-K 12 month − 10-Q 9 month · filed 2014-09-29 | $1.18M derived: sum of 2 quarters · filed 2014-09-29 | $1.93M derived: sum of 3 quarters · filed 2014-09-29 | $2.57M 10-K · filed 2014-09-29 | $21.24M 10-K/A · filed 2012-10-26 | ||||||||||||||
| 2012-03-31 | $540.79K 10-Q · filed 2013-05-15 | $1.29M derived: sum of 2 quarters · filed 2013-05-15 | $1.93M 10-Q · filed 2013-05-15 | $2.51M derived: sum of 4 quarters · filed 2013-09-11 | $20.60M 10-Q · filed 2012-05-14 | ||||||||||||||
| 2011-12-31 | $751.52K 10-Q · filed 2013-02-14 | $1.39M 10-Q · filed 2013-02-14 | $1.97M derived: sum of 3 quarters · filed 2013-09-11 | $2.77M derived: sum of 4 quarters · filed 2013-09-11 | $20.06M 10-Q · filed 2012-02-14 | ||||||||||||||
| 2011-09-30 | $634.19K 10-Q · filed 2012-11-14 | $1.22M derived: sum of 2 quarters · filed 2013-09-11 | $2.02M derived: sum of 3 quarters · filed 2013-09-11 | $2.82M derived: sum of 4 quarters · filed 2013-09-11 | $19.30M 10-Q · filed 2011-11-14 | ||||||||||||||
| 2011-06-30 | $585.19K derived: 10-K 12 month − 10-Q 9 month · filed 2013-09-11 | $1.39M derived: sum of 2 quarters · filed 2013-09-11 | $2.18M derived: sum of 3 quarters · filed 2013-09-11 | $3.72M 10-K · filed 2013-09-11 | |||||||||||||||
| 2011-03-31 | $800.34K 10-Q · filed 2012-05-14 | $1.60M derived: sum of 2 quarters · filed 2012-05-14 | $3.14M 10-Q · filed 2012-05-14 | ||||||||||||||||
| 2010-12-31 | $798.35K 10-Q · filed 2012-02-14 | $2.33M 10-Q · filed 2012-02-14 | |||||||||||||||||
| 2010-09-30 | $1.54M 10-Q · filed 2011-11-14 | ||||||||||||||||||
| 2010-06-30 | $2.64M 10-K/A · filed 2012-10-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| CHAMPIONS ONCOLOGY, INC. (CSBR) | United States | $0.070B | -68.02 |
| EXOZYMES INC. (EXOZ) | United States | $0.058B | |
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |
| ImageneBio, Inc. (IMA) | United States | $0.056B | -1.31 |
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Inmune Bio, Inc. (INMB) | United States | $0.056B | -2.48 |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |
| Tevogen Inc. (TVGN) | United States | $0.049B |